JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis

Abstract EN

Janus kinase (JAK) pathways are key mediators in the immunopathogenesis of psoriasis.

Psoriasis treatment has evolved with the advent of targeted therapies, which inhibit specific components of the psoriasis proinflammatory cascade.

JAK inhibitors have been studied in early phase trials for psoriasis patients, and the data are promising for these agents as potential treatment options.

Tofacitinib, an oral or topically administered JAK1 and JAK3 inhibitor, and ruxolitinib, a topical JAK1 and JAK2 inhibitor, have been most extensively studied in psoriasis, and both improved clinical symptoms of psoriasis.

Additional JAK1 or JAK3 inhibitors are being studied in clinical trials.

In phase III trials for rheumatoid arthritis, tofacitinib was efficacious in patients with inadequate responses to tumor necrosis factor inhibitors, methotrexate monotherapy, or disease-modifying antirheumatic drugs.

The results of phase III trials are pending for these therapies in psoriasis, and these agents may represent important alternatives for patients with inadequate responses to currently available agents.

Further investigations with long-term clinical trials are necessary to verify their utility in psoriasis treatment and assess their safety in this patient population.